{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:08:32Z","timestamp":1761016112841,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":4215,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1053\/seiz.2001.0571","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T10:55:08Z","timestamp":1032432908000},"page":"47-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities"],"prefix":"10.1053","volume":"11","author":[{"given":"Baldev K","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"White-Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/seiz.2001.0571_RF1","first-page":"41","article-title":"Antiepileptic drug status in adult outpatients with mental retardation","volume":"98 (Suppl. 1)","author":"Singh","year":"1993","journal-title":"American Journal on Mental Retardation"},{"key":"10.1053\/seiz.2001.0571_RF2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0571_RF3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400- and 600-mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0571_RF4","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0571_RF5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":"Double-blind, placebo-controlled trial of topiramate in patients with refractory epilepsy","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1053\/seiz.2001.0571_RF6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0571_RF7","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.52.7.1338","article-title":"A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children","volume":"52","author":"Elterman","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0571_RF8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":"A randomized, placebo-controlled study of topiramate in primary generalized tonic\u2013clonic seizures","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0571_RF9","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1212\/WNL.52.9.1882","article-title":"A double-blind, randomized trial of topiramate in Lennox\u2013Gastaut syndrome","volume":"52","author":"Sachdeo","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0571_RF10","first-page":"S18","article-title":"Safety of topiramate: adverse events and relationships to dosing","volume":"37 (Suppl. 2)","author":"Shorvon","year":"1996","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0571_RF11","first-page":"S56","article-title":"Practical aspects of the use of topiramate in patients with epilepsy","volume":"38 (Suppl. 1)","author":"Sander","year":"1997","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0571_RF12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131101905710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131101905710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:24:39Z","timestamp":1761009879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131101905710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["S1059131101905710"],"URL":"https:\/\/doi.org\/10.1053\/seiz.2001.0571","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/seiz.2001.0571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 BEA Trading, Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}